Skip to main content

Table 6 Proportion of patients with NDM requiring resources in France, Germany and Denmark

From: Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel

Health resource

France (%)

Germany (%)

Denmark (%)

BSC

Mexiletine

Difference

BSC

Mexiletine

Difference

BSC

Mexiletine

Difference

Physiotherapy

40

10

−30

100

100

0

25

25

0

Occupational therapist

20

10

−10

20

20

0

15

15

0

Speech therapy

30

5

−25

20

20

0

5

0

−5

Day case attendances

100

50

−50

100

100

0

5

0

−5

Use of wheelchair

10

0

−10

1

1

0

0

5

+ 5

Use of walking stick

20

10

−10

10

10

0

10

0

−10

Use of walking frame

10

5

−5

1

1

0

0

0

0

Hospital admission for fracture

5

2

−3

1

1

0

0

0

0

  1. Estimates are based on one expert per country
  2. Key: BSC Best supportive care